한글목차

본 보고서에서는 제약 및 생명공학 분야의 디스커버리 단계 제휴 조건 및 계약에 대해 조사했으며, 기업이 디스커버리 단계 제휴 조건을 체결하는 방법과 이유 및 이러한 계약을 지원하는 재무적·전략적 조건에 대해 데이터를 바탕으로 종합적으로 분석했습니다. 또한 이 보고서는 제약 및 생명공학 업계에서 초기 단계의 제휴를 정의하는 구조, 협상 역학 및 재무 고려 사항에 대한 깊은 인사이트를 제공합니다.

신약 단계에서 라이선싱 계약은 일반적으로 라이센시에게 라이센서의 제품 또는 기술을 추가로 개발할 권리 또는 옵션을 부여합니다. 이러한 계약은 종종 공동 연구 개발(R&D)로 시작하여 상업화 계약으로 이어질 수 있는 여러 요소를 포함합니다.

이 보고서는 건강 관리 분야에서 최신 의약 단계 계약의 상세한 내역을 제공하고, 기업이 시장 동향을 파악하고, 경쟁 계약 구조를 평가하고, 자사의 협상 전략을 최적화하는 데 도움이 됩니다.

이 보고서는 다음 내용을 제공합니다.

• 2020년 이후의 바이오 의약품 업계에 있어서의 디스커버리 단계의 거래 동향 분석
• 선불, 마일스톤 및 로열티 지급을 포함한 재무 구조에 대한 인사이트
• 실제 디스커버리 단계의 계약에 관한 사례 연구
• 2,690건 이상의 디스커버리 단계 안건 액세스(가용 가능한 경우는 계약 기록 첨부)
• 2020년 이후 가장 활발한 디스커버리 단계의 거래 제조업체 프로파일
• 최고액의 디스커버리 단계 안건 상세 분석

목차

주요 요약

제1장 서론

제2장 기업이 디스커버리 단계에서 제휴하는 이유

• 디스커버리 단계의 제휴 역할
  • 디스커버리 단계에서의 인라이센싱
  • 디스커버리 단계에서의 아웃라이센싱
• 디스커버리 단계, 전임상 단계, 임상 단계의 거래 차이
• 디스커버리 단계의 제휴 계약을 체결하는 이유
  • 라이센서가 디스커버리 단계의 거래에 참여하는 이유
  • 라이센시가 디스커버리 단계의 거래에 참가하는 이유
• 디스커버리 단계의 제휴 거래의 장래

제3장 디스커버리 단계의 거래 전략과 구조

• 기업은 어느 단계에서 제휴할까?
  • 제약/생명공학 분야에서의 조기 제휴
  • 제약/생명공학 분야에서의 제휴
• 초기 단계와 후기 단계의 제휴 : 위험과 비용 비교
• 기업은 디스커버리, 전임상, 임상단계의 제휴에 얼마를 소비하고 있는가?
• 순수한 제휴 계약과 복수 구성 요소 제휴 계약
• 순수한 라이선싱 계약 구조
  • 순수한 라이선싱 계약의 예
  • 사례 연구
• 복수 구성 요소 디스커버리 단계의 제휴 계약
  • 복수 구성 요소로 구성된 초기 단계 조항의 예
  • 사례 연구

제4장 디스커버리 단계의 제휴에 있어서 지불 전략

• 디스커버리 단계의 지불 전략
• 지불 옵션
  • 헤드라인
  • 선불 결제
  • 대출
  • 전환 대출
  • 지분
  • 연구개발자금
  • 라이센싱 비용
  • 마일스톤 지급
  • 로열티 지급
  • 가격
  • 옵션 지급

제5장 디스커버리 단계의 거래 동향

• 수년간의 디스커버리 단계의 제휴
• 디스커버리 단계의 제휴 : 거래 유형별
• 디스커버리 단계의 제휴 : 질환 유형별
• 디스커버리 단계의 제휴 : 기술 유형별
• 가장 활발한 기업에 의한 디스커버리 단계의 제휴

제6장 디스커버리 단계의 제휴 지불 조건

• 디스커버리 단계의 지불 조건에 관한 가이드 라인
  • 선불 결제
  • 마일스톤 지급
  • 로열티 지급
• 디스커버리 단계의 지불 조건 : 거래 데이터 분석
  • 공개 데이터
  • 조사 데이터
• 지불 조건 분석
  • 디스커버리 단계의 헤드라인 값
  • 디스커버리 단계 거래의 선불 결제
  • 디스커버리 단계 거래의 마일스톤 지급
  • 디스커버리 단계의 로열티 비율

제7장 주요 디스커버리 단계의 거래

• 상위 디스커버리 단계의 거래 : 금액별

제8장 디스커버리 단계의 거래 제조업체 상위 25개사

• 가장 활발한 디스커버리 단계의 거래 제조업체 상위 25개사

제9장 디스커버리 단계의 제휴 계약 디렉토리

• 디스커버리 단계의 거래 계약(2020-2025년)

제10장 디스커버리 단계 거래 : 개발 단계별

• 디스커버리 단계별 거래

부록

영문목차

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report offers a comprehensive, data-driven analysis of how and why companies engage in discovery-stage partnering deals and the financial and strategic terms underpinning these agreements. This essential industry resource provides deep insights into the structure, negotiation dynamics, and financial considerations that define early-stage partnerships in the pharmaceutical and biotech sectors.

At the discovery stage, licensing agreements typically grant the licensee rights or options to further develop a licensor's product or technology. These agreements are often multi-component, beginning with collaborative research and development (R&D) and potentially leading to commercialization agreements.

This report provides a detailed breakdown of the latest discovery-stage agreements in the healthcare sector, helping companies identify market trends, evaluate competitive deal structures, and optimize their own negotiation strategies.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

• Benchmarking deal structures and financial terms
• Optimizing negotiation strategies
• Assessing potential partners' flexibility and deal-making behavior
• Identifying trends and best practices in discovery-stage partnerships
• For those looking to navigate the complex landscape of discovery-stage partnering, this report offers the clarity, data, and strategic guidance needed to secure high-value agreements with the right partners.
• Why This Report is Essential for Dealmakers
• Gaining insight into the flexibility and negotiation strategies of potential partners is crucial in structuring a successful discovery-stage deal. While headline financial terms (e.g., upfront payments, milestones, and royalties) provide a broad overview, contract documents offer a deeper understanding of the actual triggers and conditions for these payments-critical details that press releases and traditional databases often omit.
• This report contains a comprehensive listing of all discovery-stage partnering deals announced since 2020, including financial terms where available. It also features over 2,690 links to detailed online deal records, including publicly available contract documents filed with the SEC.
• By analyzing these agreements, companies gain a competitive edge in structuring deals that align with industry benchmarks while maximizing potential returns.
• Comprehensive Analysis of Discovery-Stage Partnering Trends

The first chapters of the report provide a detailed orientation to discovery-stage deal-making and strategic considerations:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in discovery-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Discovery-stage deal-making analysis (2020-2025), categorized by year, therapeutic area, technology type, and key dealmakers

Chapter 6 - Detailed analysis of financial terms, including headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading discovery-stage deals by headline value

Chapter 8 - The top 25 most active discovery-stage dealmakers

Chapter 9 - A database of discovery-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all discovery-stage deals announced since 2020

• Each deal record is linked to Current Agreements, a proprietary database that provides easy access to full deal structures, financial terms, and contract documents.
• Key Benefits of the Report
• Comprehensive insights into discovery-stage deal trends since 2020
• Access to key financial terms, including headline values, upfronts, milestones, and royalty structures
• Breakdown of deal structures, with real-world case studies
• Analysis of contractual terms, including real-world clause examples
• Benchmarking of deal terms based on actual agreements
• Due diligence insights to assess the suitability of proposed deal terms for potential partners
• Scope of the Report

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

• Analysis of discovery-stage dealmaking trends in the biopharma industry since 2020
• Insight into financial structures, including upfront, milestone, and royalty payments
• Case studies of real-life discovery-stage agreements
• Access to over 2,690 discovery-stage deals, with contract records where available
• Profiles of the most active discovery-stage dealmakers since 2020
• Detailed analysis of the highest-value discovery-stage deals

Each deal record is indexed by:

• Company (A-Z)
• Headline Value
• Stage of Development at Signing
• Deal Type
• Specific Therapy Focus
• For easy access, every deal record links to an online version, and where available, the full contract document.
• Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

• What specific rights are granted in each agreement?
• What exclusivity terms apply?
• How is the deal structured financially? (Upfronts, milestones, royalties)
• How are sales and payments audited?
• Who controls development, manufacturing, and commercialization?
• How is intellectual property handled?
• How are confidentiality and publication rights managed?
• Under what conditions can a deal be terminated?
• What dispute resolution mechanisms are in place?
• What happens in the event of a change in ownership?
• Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

• 2.1. Introduction
• 2.2. The role of discovery stage partnering
  • 2.2.1. In-licensing at discovery stage
  • 2.2.2. Out-licensing at discovery stage
• 2.3. Difference between discovery, preclinical and clinical stage deals
• 2.4. Reasons for entering into discovery stage partnering deals
  • 2.4.1. Licensors reasons for entering discovery stage deals
  • 2.4.2. Licensees reasons for entering discovery stage deals
• 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

• 3.1. Introduction
• 3.2. At what stage do companies partner?
  • 3.2.1. Partnering early in pharmaceutical/biotech
  • 3.2.1.1. Discovery and preclinical stage partnering case studies
  • 3.2.1.1.a. Case study 1
  • 3.2.1.1.b. Case study 2
  • 3.2.1.1.c. Case study 3
  • 3.2.1.1.d. Case study 4
  • 3.2.2. Partnering later in pharmaceutical/biotech
  • 3.2.2.1. Clinical stage partnering case studies
  • 3.2.2.1.a. Case study 5
  • 3.2.2.1.b. Case study 6
  • 3.2.2.1.c. Case study 7
  • 3.2.2.1.d. Case study 8
• 3.3. Early and later stage partnering - a risk/cost comparison
• 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
• 3.5. Pure versus multi-component partnering deals
• 3.6. Pure licensing agreement structure
  • 3.6.1. Example pure licensing agreements
  • 3.6.1.a. Case study 9
  • 3.6.1.b. Case study 10
• 3.7. Multicomponent discovery stage partnering agreements
  • 3.7.1.a. Example multicomponent early stage clauses
  • 3.7.1.a. Case study 11
  • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

• 4.1. Introduction
• 4.2. Discovery stage payment strategies
• 4.3. Payment options
  • 4.3.1. Headline values
  • 4.3.2. Upfront payments
  • 4.3.2.1. Conditionality of upfront payments
  • 4.3.3. Loans
  • 4.3.4. Convertible loans
  • 4.3.5. Equity
  • 4.3.6. R&D funding
  • 4.3.7. Licensing fees
  • 4.3.8. Milestone payments
  • 4.3.9. Royalty payments
  • 4.3.9.1. Issues affecting royalty rates
  • 4.3.9.2. Royalties on combination products
  • 4.3.9.2.a. Case study 13
  • 4.3.9.3. Guaranteed minimum/maximum annual payments
  • 4.3.9.4. Royalty stacking
  • 4.3.9.5. Royalties and supply/purchase contracts
  • 4.3.10. Quids
  • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

• 5.1. Introduction
• 5.2. Discovery stage partnering over the years
  • 5.2.1. Attributes of discovery deals
• 5.3. Discovery stage partnering by deal type
• 5.4. Discovery stage partnering by disease type
• 5.5. Partnering by discovery stage technology type
• 5.6. Discovery stage partnering by most active company, 2020 to 2025

Chapter 6 - Payment terms for discovery stage partnering

• 6.1. Introduction
• 6.2. Guidelines for discovery stage payment terms
  • 6.2.1. Upfront payments
  • 6.2.2. Milestone payments
  • 6.2.3. Royalty payments
• 6.3. Discovery stage payment terms - deal data analysis
  • 6.3.1. Public data
  • 6.3.2. Survey data
• 6.4. Payment terms analysis
  • 6.4.1. Discovery stage headline values
  • 6.4.2. Discovery stage deal upfront payments
  • 6.4.3. Discovery stage deal milestone payments
  • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

• 7.1. Introduction
• 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

• 8.1. Introduction
• 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

• 9.1. Introduction
• 9.2. Discovery stage deals with contracts 2020 to 2025

Chapter 10 - Discovery stage deal making by development stage

• 10.1. Introduction
• 10.2. Deals by discovery stage

Appendices

• Appendix 1 - Discovery stage dealmaking by companies A-Z
• Appendix 2 - Discovery stage dealmaking by industry sector
• Appendix 3 - Discovery stage dealmaking by stage of development
• Appendix 4 - Discovery stage dealmaking by therapy area
• Appendix 5 - Discovery stage dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
• Figure 3: Components of the pure licensing deal structure
• Figure 4: Payment options for discovery stage partnering deals
• Figure 5: Issues affecting royalty rates
• Figure 6: Discovery stage partnering frequency 2020 - 2025
• Figure 7: Discovery stage partnering by deal type since 2020
• Figure 8: Discovery stage partnering by disease type since 2020
• Figure 9: Discovery stage partnering by technology type since 2020
• Figure 10: Top 25 most active discovery stage dealmakers, 2020 to 2025
• Figure 11: Review of median upfront payments for discovery stage deals
• Figure 12: Review of median milestone payments for discovery stage deals
• Figure 13: Review of median royalty payments for discovery stage deals
• Figure 14: Discovery stage deals with a headline value
• Figure 15: Discovery stage deals with an upfront value
• Figure 16: Discovery stage deals with a milestone value
• Figure 17: Discovery stage deals with a royalty rate value
• Figure 18: Top discovery stage deals by deal value since 2020
• Figure 19: Most active discovery stage dealmakers 2020 to 2025